MeTA Publications

From everyday painkillers to life saving treatments, the prescription medicines and pharmaceutical drugs we use contain ingredients that are sourced, manufactured and distributed in a variety of ways around the world.

The MeTA model represents a way of working to increase transparency and accountability in the selection, regulation, procurement, distribution, sale and use of medicines in developing countries that voluntarily choose to take part.

What difference can transparency and accountability make to access to medicines for poor people?

Despite increased government and donor financing for health, one third of the world’s population still lacks access to essential medicines. This situation persists, in part because of fundamental inefficiencies in both the pharmaceutical market and across the health and commodity supply systems of many countries.

Roles and Responsibility

An explanation of the Medicines Transparency Alliance (MeTA) and how it will work.

Common statement about WHO Good Governance for Medicines programme and DFID Medicines Transparency Alliance

The goal of the Medicines Transparency Alliance (MeTA) is to contribute to increased access to affordable essential medicines in developing countries, in cooperation with pharmaceutical companies.

The Medicines Transparency Alliance (MeTA) is designed as a global alliance where country members can participate to support their own objectives in relation to healthcare system reform.

A brief introduction to MeTA.